Target and Its Patented Drug(s)

Content Navigation (  All   None )                                      
Target General Information
Patent(s) and the Corresponding Patented Drug(s)
References
Target General Information  Top
Target ID T50773 Target Info
Target Name Dipeptidyl-peptidase 7 (DPP7)
Synonyms Quiescent cell proline dipeptidase; QPP; Dipeptidyl peptidase II; Dipeptidyl peptidase 7; Dipeptidyl peptidase 2; Dipeptidyl aminopeptidase II; DPP2; DPP II
Target Type Patented-recorded Target
Gene Name DPP7
UniProt ID
DPP2_HUMAN
Patent(s) and the Corresponding Patented Drug(s)  Top
United States Patent and Trademark Office (USPTO)
Patent ID US9346814
Title FAP inhibitors
Abstract The present invention relates to novel inhibitors having high selectivity and specificity for FAP (fibroblast activation protein). Said inhibitors are useful as a human and/or veterinary medicine, in particular for the treatment and/or prevention of FAP-related disorders such as but not limited to proliferative disorders.
Applicant(s) Universiteit Antwerp; Fox Chase Cancer Center
Representative Drug(s) D0QX2U Drug Info IC50 > 100000nM Click to Show More [1]
2 D0C6NX Drug Info IC50 > 100000nM [1]
3 D07JHU Drug Info IC50 > 100000nM [1]
4 D05FMP Drug Info IC50 > 100000nM [1]
Patent ID US9346814
Title FAP inhibitors
Abstract The present invention relates to novel inhibitors having high selectivity and specificity for FAP (fibroblast activation protein). Said inhibitors are useful as a human and/or veterinary medicine, in particular for the treatment and/or prevention of FAP-related disorders such as but not limited to proliferative disorders.
Applicant(s) Universiteit Antwerp; Fox Chase Cancer Center
Representative Drug(s) D0QX2U Drug Info IC50 > 100000nM Click to Show More [1]
2 D0C6NX Drug Info IC50 > 100000nM [1]
3 D07JHU Drug Info IC50 > 100000nM [1]
4 D05FMP Drug Info IC50 > 100000nM [1]
Patent ID US9346814
Title FAP inhibitors
Abstract The present invention relates to novel inhibitors having high selectivity and specificity for FAP (fibroblast activation protein). Said inhibitors are useful as a human and/or veterinary medicine, in particular for the treatment and/or prevention of FAP-related disorders such as but not limited to proliferative disorders.
Applicant(s) Universiteit Antwerp; Fox Chase Cancer Center
Representative Drug(s) D0QX2U Drug Info IC50 > 100000nM Click to Show More [1]
2 D0C6NX Drug Info IC50 > 100000nM [1]
3 D07JHU Drug Info IC50 > 100000nM [1]
4 D05FMP Drug Info IC50 > 100000nM [1]
Patent ID US9346814
Title FAP inhibitors
Abstract The present invention relates to novel inhibitors having high selectivity and specificity for FAP (fibroblast activation protein). Said inhibitors are useful as a human and/or veterinary medicine, in particular for the treatment and/or prevention of FAP-related disorders such as but not limited to proliferative disorders.
Applicant(s) Universiteit Antwerp; Fox Chase Cancer Center
Representative Drug(s) D0QX2U Drug Info IC50 > 100000nM Click to Show More [1]
2 D0C6NX Drug Info IC50 > 100000nM [1]
3 D07JHU Drug Info IC50 > 100000nM [1]
4 D05FMP Drug Info IC50 > 100000nM [1]
Patent ID US8470836
Title Dipeptidyl peptidase-IV inhibiting compounds, methods of preparing the same, and pharmaceutical compositions containing the same as active agent
Abstract Disclosed herein are novel compounds of Formula (1) as defined in the specification having excellent inhibitory activity against dipeptidyl peptidase-IV (DPP-IV), methods of preparing the same and pharmaceutical compositions comprising the same as an active agent.
Applicant(s) LG Life Sciences, Ltd.
Representative Drug(s) D0SH7G Drug Info IC50 > 70000nM Click to Show More [2]
2 D0MF7O Drug Info IC50 > 80000nM [2]
3 D0M6CN Drug Info IC50 > 161000nM [2]
4 D0S8CH Drug Info IC50 > 400000nM [2]
Patent ID US8470836
Title Dipeptidyl peptidase-IV inhibiting compounds, methods of preparing the same, and pharmaceutical compositions containing the same as active agent
Abstract Disclosed herein are novel compounds of Formula (1) as defined in the specification having excellent inhibitory activity against dipeptidyl peptidase-IV (DPP-IV), methods of preparing the same and pharmaceutical compositions comprising the same as an active agent.
Applicant(s) LG Life Sciences, Ltd.
Representative Drug(s) D0SH7G Drug Info IC50 > 70000nM Click to Show More [2]
2 D0MF7O Drug Info IC50 > 80000nM [2]
3 D0M6CN Drug Info IC50 > 161000nM [2]
4 D0S8CH Drug Info IC50 > 400000nM [2]
Patent ID US8470836
Title Dipeptidyl peptidase-IV inhibiting compounds, methods of preparing the same, and pharmaceutical compositions containing the same as active agent
Abstract Disclosed herein are novel compounds of Formula (1) as defined in the specification having excellent inhibitory activity against dipeptidyl peptidase-IV (DPP-IV), methods of preparing the same and pharmaceutical compositions comprising the same as an active agent.
Applicant(s) LG Life Sciences, Ltd.
Representative Drug(s) D0SH7G Drug Info IC50 > 70000nM Click to Show More [2]
2 D0MF7O Drug Info IC50 > 80000nM [2]
3 D0M6CN Drug Info IC50 > 161000nM [2]
4 D0S8CH Drug Info IC50 > 400000nM [2]
Patent ID US8470836
Title Dipeptidyl peptidase-IV inhibiting compounds, methods of preparing the same, and pharmaceutical compositions containing the same as active agent
Abstract Disclosed herein are novel compounds of Formula (1) as defined in the specification having excellent inhibitory activity against dipeptidyl peptidase-IV (DPP-IV), methods of preparing the same and pharmaceutical compositions comprising the same as an active agent.
Applicant(s) LG Life Sciences, Ltd.
Representative Drug(s) D0SH7G Drug Info IC50 > 70000nM Click to Show More [2]
2 D0MF7O Drug Info IC50 > 80000nM [2]
3 D0M6CN Drug Info IC50 > 161000nM [2]
4 D0S8CH Drug Info IC50 > 400000nM [2]
References  Top
REF 1 FAP inhibitors. US9346814.
REF 2 Dipeptidyl peptidase-IV inhibiting compounds, methods of preparing the same, and pharmaceutical compositions containing the same as active agent. US8470836.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.